BASF Faces a Narrowing Margin of Error as Q3 Results Approach
Published on 08/29/2026 at 13:23 | Editorial boerse-global.de
The gap between BASF's share price and what analysts think it is worth has shrunk to a sliver. Morningstar cut its fair value estimate for the German chemicals giant to €55.00 from €61.00 on Thursday, leaving just 5 percent of upside over Friday's closing price of €52.28 — a far cry from the comfortable cushion investors enjoyed earlier in the year.
The revision reflects a sobering reality check on the cyclical recovery thesis. Morningstar points to structural overcapacity in China and a sluggish market cycle turnaround as the key drags, even as it upgraded BASF's capital allocation rating to "Standard." The six-euro reduction in fair value signals that the market's hopes for a swift rebound may be running ahead of fundamentals.
A Logistics Squeeze Adds to the Pressure
Compounding the demand-side concerns, low water levels on the Rhine are crimping BASF's supply chains. The company has been forced to lean more heavily on its combined transport transshipment terminal in Ludwigshafen to reroute deliveries by rail and road, as the river — historically the site's lifeline for raw material inflows and product outflows — becomes less dependable.
The logistical strain has prompted pricing action. BASF is raising prices on all grades of its NEOL-branded neopentyl glycol in the US and Canada effective September 1, citing higher costs. The move illustrates the company's attempt to pass on expense pressures to customers even as demand in parts of the chemicals sector remains tepid.
Portfolio Overhaul Gathers Pace
These operational headaches arrive amid one of the most aggressive portfolio restructurings in BASF's recent history. The sale of the Coatings business to Carlyle closed at the end of June, generating a post-tax disposal gain of €3.5 billion. The EU Commission approved the transaction in June with conditions attached — Carlyle must divest Nouryon's global polysulfide business.
The divestment machine has kept running. In May, BASF agreed to sell its silicates business, including the Düsseldorf site, to PQ, with completion expected in the second half of the year. March saw the agricultural division acquire biologicals company AgBiTech.
The strategic logic behind these moves is clear: they pave the way for the planned initial public offering of the Agricultural Solutions division on the Frankfurt Stock Exchange by 2027. The agribusiness unit is also burnishing its technology credentials ahead of the listing, having recently launched "xarvio CONNECT 2.0," a connectivity device that digitally links farm machinery with the xarvio FIELD MANAGER and includes an integrated SIM card for areas with poor mobile coverage.
Buybacks and Balance Sheet Discipline
The divestment proceeds are being recycled into shareholder returns. BASF has initiated a share buyback program of up to €1.0 billion running from August 2026 to the end of April 2027. That follows a prior buyback tranche between November 2025 and June 2026, during which the company repurchased shares worth €1.5 billion — 31.6 million shares, or roughly 3.5 percent of share capital, are being cancelled.
Debt reduction is also on the agenda. The company plans early repayment of bonds and loans with a nominal volume of €1.6 billion in the third quarter, a move that would trim financing costs.
When operational pressures mount, the last thing you need is uncertainty around compliance and risk management. A free toolkit with 41 ready-to-use templates and checklists helps you document workplace risks properly and stay on top of your legal duties — so you can focus on keeping your business moving. Download the free Risk Assessment Toolkit
The Q3 Test
The immediate catalyst for the stock, however, is the third-quarter earnings release on October 28. The second quarter delivered a clear beat — EBITDA before special items of €2.4 billion, well above consensus, on revenue of €17.2 billion, up 16 percent. Management responded by lifting full-year guidance to €6.9–7.7 billion EBITDA before special items, from a prior range of €6.2–7.0 billion.
The question now is whether that momentum carries through. The lower end of the new guidance band sits only modestly above the old target corridor, leaving little room for a demand stumble in the chemicals core. A cyclical setback could quickly put the upper bound out of reach.
Bears also note that the stock, trading 5.6 percent above its 50-day average of €49.51 and 7.4 percent above the 200-day average of €48.68, has already priced in a fair amount of optimism. The shares sit about 5.0 percent below the 52-week high of €55.05 hit in April, but a full 26 percent above the low of €41.55.
The IPO timeline for the agribusiness unit remains an intention with a 2027 horizon rather than a firm date — delays or an unfavorable market window could push it out. And the silicates sale to PQ, while agreed, has yet to close.
For now, the bull case rests on the buyback, the balance sheet discipline, and a leaner portfolio unlocking value. The bear case rests on China's overcapacity, a Rhine that keeps running low, and a valuation that has caught up with reality. The October 28 conference call will show which narrative has the upper hand.
